You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):糖尿病治療藥物"西格列汀二甲雙胍緩釋片"首仿獲批上市
格隆匯 01-10 17:45

格隆匯1月10日丨中國生物製藥(01177.HK)宣佈,集團開發的治療糖尿病藥物"西格列汀二甲雙胍緩釋片"(商品名:品多)已獲中國國家藥品監督管理局頒發藥品註冊證書。該產品按化藥3類申報,視同通過仿製藥質量和療效一致性評價,同品種國內仿製藥首家獲批上市。

西格列汀二甲雙胍緩釋片適用於正在接受西格列汀和二甲雙胍聯合治療的成人2型糖尿病患者。磷酸西格列汀是一種口服的高度選擇性二肽基肽酶-4(DPP-4)抑制劑,二甲雙胍是目前糖尿病用藥指南推薦的一線用藥。隨着治療時間的延長,單藥治療的血糖控制達成率會呈現逐漸下降。研究表明,將磷酸西格列汀與傳統降糖藥二甲雙胍聯合使用,能提高血糖控制達成率,而不增加不良反應。西胍組合為國內外治療指南所推薦。

西格列汀二甲雙胍緩釋片劑相比普通片劑,每日僅需服藥1次,服用更方便。該產品獲批上市,將為國內糖尿病患者帶來更佳的治療選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account